Cargando…
Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study
PURPOSE: To evaluate the outcomes of water-soluble intrastromal natamycin (IS-NTM) as an adjunct therapy for recalcitrant fungal keratitis. METHODS: This was a prospective interventional pilot study in the setting of a tertiary eye-care center. Twenty eyes of 20 consecutive patients with microbiolog...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597472/ https://www.ncbi.nlm.nih.gov/pubmed/34571612 http://dx.doi.org/10.4103/ijo.IJO_73_21 |
_version_ | 1784600610767634432 |
---|---|
author | Saluja, Gunjan Sharma, Namrata Agarwal, Rinky Sharma, H P Maharana, Praful Satpathy, Gita Titiyal, Jeewan Singh Velpandian, T |
author_facet | Saluja, Gunjan Sharma, Namrata Agarwal, Rinky Sharma, H P Maharana, Praful Satpathy, Gita Titiyal, Jeewan Singh Velpandian, T |
author_sort | Saluja, Gunjan |
collection | PubMed |
description | PURPOSE: To evaluate the outcomes of water-soluble intrastromal natamycin (IS-NTM) as an adjunct therapy for recalcitrant fungal keratitis. METHODS: This was a prospective interventional pilot study in the setting of a tertiary eye-care center. Twenty eyes of 20 consecutive patients with microbiologically proven recalcitrant fungal keratitis (ulcer size >2 mm, depth >50%, and not responding to topical NTM for 2 weeks) were recruited. The selected patients were injected with a novel composition of IS-NTM (10 ug/0.1 mL, soluble natamycin) prepared aseptically in the ocular pharmacology department. All the patients continued using topical NTM suspension 5% 4-hourly until the ulcer healed. Repeat injections were undertaken after 72 h depending on the clinical response and all the patients were followed till 6 months. RESULTS: The mean age of the patients was 40.42 ± 10.09 years. The mean duration of the presentation was 20.8 ± 5.1 days. The most commonly isolated organisms were Aspergillus sp. (12/20, 60%) and Fusarium sp. (8/20, 40%). No patient had iatrogenic perforation or precipitate formation after IS-NTM injection. The overall cure rate with IS-NTM was 95% (19/20 patients). The number of patients who healed with the 1(st), 2(nd), and 3(rd) injection was 13, 5, and 1, respectively. One (5%) had no response to treatment and was subjected to penetrating keratoplasty. The average time taken for the resolution of the epithelial defect, stromal infiltrates, and hypopyon was 34 ± 5.2 days, 35.3 ± 6.4 days, and 15 ± 2.5 days. Healing with deep vascularization and cataract was noted in 6/19 eyes (31%) and 13/19 eyes (68.42%), respectively. CONCLUSION: Intrastromal injection of a novel formulation of NTM holds a promising role as adjunctive therapy to topical NTM in the management of recalcitrant filamentous fungal keratitis. The preliminary results are encouraging and further studies are required to validate the results. |
format | Online Article Text |
id | pubmed-8597472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-85974722021-12-07 Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study Saluja, Gunjan Sharma, Namrata Agarwal, Rinky Sharma, H P Maharana, Praful Satpathy, Gita Titiyal, Jeewan Singh Velpandian, T Indian J Ophthalmol Original Article PURPOSE: To evaluate the outcomes of water-soluble intrastromal natamycin (IS-NTM) as an adjunct therapy for recalcitrant fungal keratitis. METHODS: This was a prospective interventional pilot study in the setting of a tertiary eye-care center. Twenty eyes of 20 consecutive patients with microbiologically proven recalcitrant fungal keratitis (ulcer size >2 mm, depth >50%, and not responding to topical NTM for 2 weeks) were recruited. The selected patients were injected with a novel composition of IS-NTM (10 ug/0.1 mL, soluble natamycin) prepared aseptically in the ocular pharmacology department. All the patients continued using topical NTM suspension 5% 4-hourly until the ulcer healed. Repeat injections were undertaken after 72 h depending on the clinical response and all the patients were followed till 6 months. RESULTS: The mean age of the patients was 40.42 ± 10.09 years. The mean duration of the presentation was 20.8 ± 5.1 days. The most commonly isolated organisms were Aspergillus sp. (12/20, 60%) and Fusarium sp. (8/20, 40%). No patient had iatrogenic perforation or precipitate formation after IS-NTM injection. The overall cure rate with IS-NTM was 95% (19/20 patients). The number of patients who healed with the 1(st), 2(nd), and 3(rd) injection was 13, 5, and 1, respectively. One (5%) had no response to treatment and was subjected to penetrating keratoplasty. The average time taken for the resolution of the epithelial defect, stromal infiltrates, and hypopyon was 34 ± 5.2 days, 35.3 ± 6.4 days, and 15 ± 2.5 days. Healing with deep vascularization and cataract was noted in 6/19 eyes (31%) and 13/19 eyes (68.42%), respectively. CONCLUSION: Intrastromal injection of a novel formulation of NTM holds a promising role as adjunctive therapy to topical NTM in the management of recalcitrant filamentous fungal keratitis. The preliminary results are encouraging and further studies are required to validate the results. Wolters Kluwer - Medknow 2021-10 2021-09-25 /pmc/articles/PMC8597472/ /pubmed/34571612 http://dx.doi.org/10.4103/ijo.IJO_73_21 Text en Copyright: © 2021 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Saluja, Gunjan Sharma, Namrata Agarwal, Rinky Sharma, H P Maharana, Praful Satpathy, Gita Titiyal, Jeewan Singh Velpandian, T Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study |
title | Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study |
title_full | Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study |
title_fullStr | Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study |
title_full_unstemmed | Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study |
title_short | Determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: A pilot study |
title_sort | determination of surgical outcomes with a novel formulation of intrastromal natamycin in recalcitrant fungal keratitis: a pilot study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597472/ https://www.ncbi.nlm.nih.gov/pubmed/34571612 http://dx.doi.org/10.4103/ijo.IJO_73_21 |
work_keys_str_mv | AT salujagunjan determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT sharmanamrata determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT agarwalrinky determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT sharmahp determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT maharanapraful determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT satpathygita determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT titiyaljeewansingh determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy AT velpandiant determinationofsurgicaloutcomeswithanovelformulationofintrastromalnatamycininrecalcitrantfungalkeratitisapilotstudy |